We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 24, 2022

Neoadjuvant Treatment ± Atezolizumab in High-Risk TNBC

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study
Ann. Oncol 2022 Feb 16;[EPub Ahead of Print], L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, S Zambelli, G Bianchini, S Russo, EM Ciruelos, R Greil, V Semiglazov, M Colleoni, C Kelly, G Mariani, L Del Mastro, I Maffeis, P Valagussa, G Viale

Further Reading